Drug intelligence / Profile preview

CBT-104D

Development stage: Unknown
Lead developer: CommBio Therapeutics
Modality: Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics

Overview

CBT-104D is an engineered bacterial therapeutic being developed by CommBio Therapeutics for the treatment of Graft-versus-Host Disease (GvHD). As a live biotherapeutic product (LBP), it consists of genetically modified bacteria designed to modulate the immune system or the intestinal environment to mitigate the inflammatory response associated with GvHD, a common and potentially fatal complication following allogeneic hematopoietic stem cell transplantation. The platform involves engineering specific bacterial strains to deliver therapeutic payloads or perform metabolic functions directly within the gut. CBT-104D is currently in the clinical research stage, aimed at addressing the high unmet need for effective GvHD treatments that can manage systemic inflammation while preserving the graft-versus-tumor effect.

Beyond the preview

Go deeper on CBT-104D.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on CBT-104D.

Explore the full profile